Skip to main content

Month: February 2023

Stand-Up Pouches Market Set to Reach $20.12 Billion by 2026 | With a CAGR of 7.73%

key players operating in the stand-up pouches market are The Smurfit Kappa Group plc, Sonoco Products Company, ProAmpac, Berry Global, Inc, Amcor plc, Sealed Air Corporation, Bemis Company, Inc, Coveris and more Pune, India, Feb. 13, 2023 (GLOBE NEWSWIRE) — The global stand-up pouches market size is expected to reach USD 20.12 billion by 2026. Stand-up pouches, also known as stand-up bags or doypacks, are flexible packaging bags that are designed to stand upright on their own, hence the name. These pouches are made from multiple layers of materials, including a barrier layer to preserve the freshness and quality of the contents, and a bottom gusset that allows them to expand and stand up. Stand-up pouches are widely used for packaging a variety of products, including food, beverages, household items, personal care products, and...

Continue reading

Press Release: Sanofi announces change in R&D leadership

  Sanofi announces change in R&D leadership Paris, February 13, 2023. Sanofi announced today that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. The company warmly thanks Dr. Reed for his leadership over these last years. Since joining Sanofi in 2018, John has laid the foundation for the company’s R&D transformation. He helped reshape Sanofi’s discovery and development of therapeutics, focusing efforts on first and best in class medicines that have the potential to transform the practice of medicine and improve the lives of people with serious diseases, whilst managing the integration and development of new technology platforms and partnerships, and driving R&D productivity. In 2023, Sanofi will launch two first or best-in-class medicines that will address...

Continue reading

After record growth last year, Novaturas is recognised by Nasdaq for excellence in overcoming challenges

Novaturas Group, the leader in the Baltic tourism market, was recognised at the Nasdaq Baltic Awards 2023 as the company that did the best job overcoming recent challenges and managing market change. Novaturas won the title of “The Challenge of the Year” – an award specially established by Nasdaq Vilnius for the most significant contribution to the development of the Lithuanian and Baltic capital markets. The income achieved in 2022 reflects the company’s balanced and targeted growth.   “There was no shortage of challenges last year – when the war started in Ukraine, tourism demand dropped significantly and the price of jet fuel increased drastically, which temporarily led to a considerable decrease in profitability. However, after a tough first half, we returned to the path of profitability by summer. In Q3 2022, EBITDA increased to EUR...

Continue reading

Additional Employee Representative appointed to SkiStar’s Board of Directors

SkiStar AB (publ) today announces that Tobias Englund has been appointed as Unionen’s employee representative in the Board of Directors of SkiStar AB, effective from 9 May 2023. Following this decision, SkiStar’s Board of Directors thereafter includes – in addition to the seven members appointed by the general meeting of shareholders – two employee representatives, appointed by Unionen respectively Hotell- och Restaurangfacket. This information was submitted for publication, through the agency of the contact persons set out below, at 13 February 2023, 08.50 a.m. CET. Further information can be reached from: Stefan Sjöstrand, CEO, tel +46 (0)280 841 60.Anders Örnulf, CFO, tel +46 (0)280 841 60. SkiStar in brief SkiStar AB (publ) is listed on the Mid Cap list of the Nasdaq Stockholm exchange. The Group owns and operates mountain resorts...

Continue reading

Spar Nord Bank A/S launches share buyback programme

Company announcement no. 08 As announced in company announcement no. 7/2023 (Annual Report 2022), Spar Nord is launching a share buyback programme of up to DKK 300 million with a view to reducing the Bank’s share capital by the shares acquired under the programme. Based on the closing price on 10 February 2023, this corresponds to around 2.5 million shares. The purpose of the share buyback is to optimise the Bank’s capital structure in accordance with the announced capital targets. At the end of Q4 2022, Spar Nord had a common equity tier 1 (CET1) ratio of 16.4%, while the own funds ratio was 20.9%. The effect of the share buyback programme is a deduction of 0.5 of a percentage point, which will be recognised in Q1 2023. Spar Nord pursues the goal of having a common equity tier 1 (CET1) ratio of 13.5% and an own funds ratio of 17.5%. The...

Continue reading

Wearable AI Device Market is Predicted to Surpass a Revenue of USD 69.31 Billion by Growing at Notable a CAGR of 26.10% During 2022-2028; Growing Adoption of Artificial Intelligence and Rising Health Awareness Among People to Drive Market G

A recent market report by SkyQuest on wearable AI device provides a thorough assessment of the industry’s competitive environment and developing trends. Along with an evaluation of the top competitors and their strategies, it contains a detailed analysis of market size, share, growth, and profitability. The research also examines market prospects, challenges, and pricing trends, giving investors the most recent data and insightful analysis to help them make wise decisions. Readers may remain on top of market trends and developments with the help of the report’s in-depth analysis. Westford, USA, Feb. 13, 2023 (GLOBE NEWSWIRE) — The wearable AI device market in the North America region is predicted to gain the biggest market share during the forecast period by growing at a significant CAGR. The market’s expansion...

Continue reading

Cardioverter Defibrillator Device Market is Predicted Attain a Revenue of 17.7795 Billion by Growing at a CAGR of 7.1% During 2022-2028; Increasing Prevalence of Cardiovascular Diseases to Elevate Market Growth – SkyQuest

The most recent cardioverter defibrillator device market analysis by SkyQuest forecasts potential future development and offers up-to-date details on sales volume, industry trends, and anticipated growth. By providing a thorough market analysis, the research intends to assist decision-makers in making smart investment decisions. Key market drivers, obstacles, and opportunities are also identified by the research. Additionally, the report also contains a section on regional analysis that focuses on areas with significant growth potential and aids players in boosting their market presence. Westford, USA, Feb. 12, 2023 (GLOBE NEWSWIRE) — The cardioverter defibrillator device market in North America is on an upward trajectory owing to several factors including the increasing usage of advanced technologies by healthcare organizations,...

Continue reading

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1   The acute migraine drug market size is expected to reach US$9.26 billion by 2030.3 There is strong evidence for use of NSAIDs as first-line treatment for migraine, and celecoxib is in same class of agents, fast acting and has the potential to have the lowest GI side effects of all NSAIDs.2 ELYXYBTM has the potential to further expand Scilex’s non-opioid portfolio in broader acute pain indications and its acquisition establishes a growth platform for Scilex and fits within Scilex’s existing commercial team. The pain management therapeutics market size is estimated to reach US$ 101.27 billion by 2029 and growing at a CAGR of 4.3% from 2022 to 2030.4 ELYXYBTM is protected by six...

Continue reading

HII Employees Honored at 37th annual Black Engineer of the Year (BEYA) Award STEM Conference

HII award winners at BEYA 2023 Seven employees from HII’s Newport News Shipbuilding, Ingalls Shipbuilding and Mission Technologies divisions were recognized for achievements in the science, technology, engineering and math fields during the 37th annual Black Engineer of the Year Award (BEYA) STEM Conference.NEWPORT NEWS, Va., Feb. 11, 2023 (GLOBE NEWSWIRE) — Global all-domain defense provider HII (NYSE: HII) announced today that seven employees from its Newport News Shipbuilding, Ingalls Shipbuilding and Mission Technologies divisions were recognized for achievements in the science, technology, engineering and math fields during the 37th annual Black Engineer of the Year Award (BEYA) STEM Conference. The conference took place this week at the Gaylord Convention Center in National Harbor, Md. “I am incredibly proud of these...

Continue reading

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects OTX-TKI continued to be generally well tolerated with no drug-related serious adverse events through Month 10 Conference call to discuss results to be held on Monday, February 13 at 8:30 a.m. ET BEDFORD, Mass., Feb. 11, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced interim 10-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.